Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avanos Medical ( (AVNS) ) has shared an update.
On September 15, 2025, Avanos Medical announced the acquisition of Nexus Medical, a company known for its TKO® anti-reflux needleless connector technology. This acquisition aims to enhance Avanos’ Specialty Nutrition Systems business by integrating Nexus’ technology, which supports safer nutrition and medication delivery in critical care settings like NICUs and PICUs. The acquisition is expected to immediately boost Avanos’ revenue growth and earnings per share, reinforcing its strategy to provide innovative solutions in critical care.
The most recent analyst rating on (AVNS) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Avanos Medical stock, see the AVNS Stock Forecast page.
Spark’s Take on AVNS Stock
According to Spark, TipRanks’ AI Analyst, AVNS is a Neutral.
Avanos Medical’s overall stock score reflects strong revenue growth and strategic initiatives to address challenges. However, significant profitability issues, a negative P/E ratio, and potential liquidity concerns weigh down the score. Technical indicators show mixed signals, with short-term bullish momentum but longer-term challenges. The earnings call provided a balanced view of growth and challenges, contributing positively to the score.
To see Spark’s full report on AVNS stock, click here.
More about Avanos Medical
Avanos Medical is a medical technology company headquartered in Alpharetta, Georgia, focused on delivering clinically superior medical device solutions. The company addresses critical healthcare needs, such as providing nutrition from hospital to home and reducing opioid use, and holds leading market positions globally in multiple product categories.
Average Trading Volume: 591,964
Technical Sentiment Signal: Sell
Current Market Cap: $567M
See more insights into AVNS stock on TipRanks’ Stock Analysis page.